Serum cystatin C as an early marker of nephropathy among type 2 diabetics: A meta-analysis.
The varying views as to the usefulness of serum cystatin C (CysC) as an early marker of diabetic nephropathy (DN) prompted us to investigate existing literature to determine whether serum CysC can be used as an early marker of DN using a meta-analysis approach. Twelve studies written in English were retrieved from PubMed using various key search terms. Data were extracted from the included studies by two of the authors and was subjected to statistical analysis using Review Manager 5.3 and Meta-Essentials. Levels of serum CysC were compared between the study groups using the standardized mean difference (SMD) and 95% confidence interval (CI). Overall outcomes indicate that serum CysC levels are higher among those with microalbuminuria (MI) and macroalbuminuria (MA) than those in the control group (CN) and those with normoalbuminuria (NO). However, these findings were heterogeneous, which warranted an investigation using the Galbraith plot. Heterogeneity was either reduced or lost in the post-outlier outcomes indicating combinability of the studies. Serum CysC is shown to be a superior biomarker in the early diagnosis of DN. However, further studies are still needed to verify our claims.